Showing results (361-370 of 824) with videos related to
Sort By:
Pageof 83
Blood|July 25, 2025
Safety and Efficacy of Elranatamab in Patients with Relapsed and/or Refractory immunoglobulin Light-Chain AmyloidosisPedro Vianna, Rajshekhar Chakraborty, Shahrier Hossain, et al.The Lancet. Haematology|March 28, 2020
Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 studyPaul G Richardson, Sara Bringhen, Peter Voorhees, et al.Nature Chemical Biology|October 3, 2017
Inhibition of USP10 induces degradation of oncogenic FLT3Ellen L Weisberg, Nathan J Schauer, Jing Yang, et al.British Journal of Haematology|January 12, 2011
Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancersPaul G Richardson, Constantine S Mitsiades, Jacob P Laubach, et al.Journal of Leukemia (Los Angeles, Calif.)|September 27, 2016
Lenalidomide Polarizes Th1-specific Anti-tumor Immune Response and Expands XBP1 Antigen-Specific Central Memory CD3+CD8+ T cells against Various Solid TumorsJooeun Bae, Derin B Keskin, Kristen Cowens, et al.Expert Opinion on Emerging Drugs|March 16, 2007
Emerging drugs in multiple myelomaIrene M Ghobrial, Xavier Leleu, Evdoxia Hatjiharissi, et al.Annals of Hematology|January 24, 2018
The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myelomaIris Breitkreutz, Klaus Podar, Vianihuini Figueroa-Vazquez, et al.Journal of Immunology (Baltimore, Md. : 1950)|January 8, 2013
Heat shock protein 90 is critical for regulation of phenotype and functional activity of human T lymphocytes and NK cellsJooeun Bae, Aditya Munshi, Cheng Li, et al.Leukemia & Lymphoma|May 20, 2009
Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms MacroglobulinemiaJacob P Laubach, Constantine S Mitsiades, Aldo M Roccaro, et al.Clinica Chimica Acta; International Journal of Clinical Chemistry|December 15, 2010
Serial serum free light chain measurements do not detect changes in disease status earlier than electrophoretic M-spike measurements in patients with intact immunoglobulin myelomaSacha N Uljon, Paul G Richardson, Peter H Schur, et al.Pageof 83